All News
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, Quizes and journal articles this week on the podcast.
Read Article
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.
Read Article
A Role for Plasmacytoid Dendritic Cells in Lupus
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and, importantly, what we still don't know.
Read Article
Early GI Involvement Predictive of Scleroderma Outcomes
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
Read Article
Hydroxychloroquine: 5 mg/kg/day Is Only the Starting Point
Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival.
Read Article
HCQ: 5 mg/kg/day Is Only the Starting Point
HCQ is one of the most important drugs in rheumatology, especially for SLE. It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if https://t.co/Fwr92tuZf2
Dr. John Cush RheumNow ( View Tweet)
Does Exercise and Lifestyle Modification Improve RA?
Do exercise or lifestyle modifications reduce the risk of getting RA or change those with early RA? A current review and meta-analysis found no studies addressing the benefit in pre-clinical RA, but found evidence that https://t.co/Bvp3Ery5Fg
Dr. John Cush RheumNow ( View Tweet)
Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj
Dr. John Cush RheumNow ( View Tweet)
Two experts unpack the updated ACR guidelines + the real-world nuances of managing lupus nephritis.
A practical, balanced perspective for clinicians.
Sponsored by Aurinia
https://t.co/HYuucoFmDA https://t.co/odOAqkRAHy
Dr. John Cush RheumNow ( View Tweet)
Press release of early study of IMVT-1402 (human mAb targeting FcRn) Open-label Rx in 170 active, refractory RA showed ACR 20/50/70 of 73%/54%/36% at wk 16. Next, Responders will do a blinded withdrawl - blinded results to follow. https://t.co/Mzmb3PPvMF https://t.co/oZ99l9VJQU
Dr. John Cush RheumNow ( View Tweet)
NLRP3 inflammasome activation triggers PAD (2, 4) release from human neutrophils, increasing citrullination of intracellular proteins (CCPs) and driving the pathogenesis of #RA. Further proof: , PAD concentrations and PAD activity correlate with IL-1β.https://t.co/pRQy0ECG5d https://t.co/SlLO35JhvY
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s global faculty reporters help translate the data into clinical practice.
Featuring:
✨ Dr. Janet Pope (@Janetbirdope)
✨ Dr. Yuz Yusof (@Yuz6Yusof)
✨ Dr. Jiha Lee (@JihaRheum)
✨ Dr. Mrinalini Dey (@DrMiniDey)
✨ Dr. Aurelie Najm (@AurelieRheumo)
✨ Dr. Bella https://t.co/0Pm0uUwRNf
Dr. John Cush RheumNow ( View Tweet)
True or False: In a registry of SLE patients, RNP-positive patients showed lower disease activity and less prednisone use. If you think you know the answer, prove it in this week's RheumIQ quiz at https://t.co/DTabBEfjj9
Dr. John Cush RheumNow ( View Tweet)
Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm in Japan. Drug was released in June 2022, since its been given to ~8,500 pts. Avacopan safety is being reviewed by FDA with Amgen. https://t.co/ri0nROCL5U https://t.co/jbksrWMFwI
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a dosing update for burosumab-twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH). https://t.co/EPyp6tDsaf https://t.co/1HEaQRk9BR
Dr. John Cush RheumNow ( View Tweet)
Goofy study of the month! (pub in JAMA!) RCT 170 adults w/ chronic LBP + MRI disc herniation found that amoxicillin-clavulanate, 500 mg/125 mg bid x 3 mos did not improve pain at 3 or 12 mos (vs PBO). Whatha... https://t.co/njrw6itAP8 https://t.co/CW2ssNPxf1
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 40 newly Dx, Tx-naïve RA pts starting MTX; Of serum cytokines tested, high baseline IL-6 & IL-17 was assoc w/ nonresponse to MTX. Yet, still not good response biomarkers. TNF-α & GM-CSF did not assoc w/ MTX outcomes https://t.co/YIQKop9LMH https://t.co/XxwcRsKwoM
Dr. John Cush RheumNow ( View Tweet)
Israel study 264,858 pregnancies- 1st trimester NSAID exposure had no risk of congenital malformations (MCM). 8% exposed vs unexposed: overall MCM 8.2% v 7%; aRR 0.99). MCMs not incr = MSK, CV, CNS, cleft palate, GI, GU, nonsignif MSM aRR from 0.77- 1.05 https://t.co/ytYhBFl44o https://t.co/1fq4D1KykM
Dr. John Cush RheumNow ( View Tweet)
ABA versus HCQ in Palindromic Rheumatism
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. https://t.co/z0ptEYdhQj
Dr. John Cush RheumNow ( View Tweet)
APR: Fibromyalgia
Dr. Jack Cush reviews Fibromyalgia as part of the Advanced Practice Rheum video series.
https://t.co/jq6dSXy6SU https://t.co/bDGRhhY2D9
Links:
Dr. John Cush RheumNow ( View Tweet)
